Sequential chemotherapy and icotinib as first-line treatment for advanced epidermal growth factor receptor-mutated non-small cell lung cancer

Table 4 Possible treatment-related adverse events

	All-grade TRAE		Grade 3-4 TRAE
	Icotinib (n = 22)	Chemotherapy + icotinib (n = 34)	Icotinib (n = 22)	Chemotherapy + icotinib (n = 34)
Rash	9 (40.9)	19 (55.9)	0 (0.0)	0 (0.0)
Gastrointestinal system disorders	0 (0.0)	28 (82.4)	0 (0.0)	2 (5.9)
Alanine transaminase elevation	6 (27.3)	14 (41.2)	0 (0.0)	0 (0.0)
Aspartate aminotransferase elevation	3 (13.6)	10 (29.4)	0 (0.0)	0 (0.0)
Leukopenia	0 (0.0)	22 (64.7)	0 (0.0)	3 (8.8)
Thrombocytopenia	0 (0.0)	4 (11.8)	0 (0.0)	0 (0.0)

TRAE: Treatment-related adverse event.